Smart nanocarriers as therapeutic platforms for bladder cancer

Tong, Tongyu; Guan, Yupeng; Gao, Yuanji; Chen, Xing; Zhang, Shiqiang; Jiang, Donggen; Yang, Xiangwei; Kang, Yang; Pang, Jun

doi:10.1007/s12274-021-3753-9

Cited by 9 publications

(8 citation statements)

References 158 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the standard therapeutic schedule for bladder cancer patients, surgical transurethral resection may incompletely resect, or miss, small malignant lesions that have the potential to lead to recurrence [91]. To avoid recurrence and progression after surgery, intravesical instilled chemotherapy and immunotherapy allow cancer lesions to be directly exposed to therapeutic agents, and are widely accepted as adjuvant therapies [92]. However, there are still lots of problems with conventional intravesical chemotherapy and immunotherapy.…”

Section: Nanocarriers-based Intravesical Delivery For Chemotherapy Of...mentioning

confidence: 99%

“…The uroplakins and transmembrane proteins consist of covering plaques, tight cell junctions, and the glycosaminoglycan mucin layer of the mucosal layer, prevent the therapeutical agents from effectively penetrating into tumors [93][94][95]. Additionally, the filling of the bladder causes an urge to urinate and the concentration of the therapeutic agent can be diluted by urine [92]. To maintain the concentration, frequent catheterizations are necessary but these lead to bladder irritation, infection, fibrosis and inflammation [11].…”

Section: Nanocarriers-based Intravesical Delivery For Chemotherapy Of...mentioning

confidence: 99%

“…Nowadays, advances in nanomedicine and biomaterials have indicated a high-profile and promising pathway to deliver anticancer agents and improve current therapies. Moreover, many clinical trials of nanostructurebased chemotherapy in bladder cancer have been conducted [92]. This section will focus on the nanomedicine-based novel drug delivery system for intravesical chemotherapy.…”

Section: Nanocarriers-based Intravesical Delivery For Chemotherapy Of...mentioning

confidence: 99%

“…Although intravesical chemotherapy and immunotherapy are generally accepted as adjuvant treatments after surgery to avoid recurrence, these treatments still have restrictions, including the ineffective permeability of chemotherapeutic agents and dilution of the agents by urine [92]. To compensate for the defects of traditional therapy, a new therapeutic method called sonodynamic therapy (SDT) was developed, which kills malignant tumor cells by using sonosensitizers and low-intensity ultrasound (US), simultaneously [141].…”

Section: Sonodynamic Therapy Of Bladder Cancermentioning

confidence: 99%

See 3 more Smart Citations

Recent Progress in Nanomaterial-Based Biosensors and Theranostic Nanomedicine for Bladder Cancer

Song

Ding

et al. 2023

Biosensors

View full text Add to dashboard Cite

Bladder cancer (BCa) is one of the most expensive and common malignancies in the urinary system due to its high progression and recurrence rate. Although there are various methods, including cystoscopy, biopsy, and cytology, that have become the standard diagnosis methods for BCa, their intrinsic invasive and inaccurate properties need to be overcome. The novel urine cancer biomarkers are assisted by nanomaterials-based biosensors, such as field-effect transistors (FETs) with high sensitivity and specificity, which may provide solutions to these problems. In addition, nanomaterials can be applied for the advancement of next-generation optical imaging techniques and the contrast agents of conventional techniques; for example, magnetic resonance imaging (MRI) for the diagnosis of BCa. Regarding BCa therapy, nanocarriers, including mucoadhesive nanoparticles and other polymeric nanoparticles, successfully overcome the disadvantages of conventional intravesical instillation and improve the efficacy and safety of intravesical chemotherapy for BCa. Aside from chemotherapy, nanomedicine-based novel therapies, including photodynamic therapy (PDT), photothermal therapy (PTT), chemodynamic therapy (CDT), sonodynamic therapy (SDT), and combination therapy, have afforded us new ways to provide BC therapy and hope, which can be translated into the clinic. In addition, nanomotors and the nanomaterials-based solid tumor disassociation strategy provide new ideas for future research. Here, the advances in BCa diagnosis and therapy mentioned above are reviewed in this paper.

show abstract

Section: Nanocarriers-based Intravesical Delivery For Chemotherapy Of...mentioning

confidence: 99%

Section: Nanocarriers-based Intravesical Delivery For Chemotherapy Of...mentioning

confidence: 99%

Section: Nanocarriers-based Intravesical Delivery For Chemotherapy Of...mentioning

confidence: 99%

Section: Sonodynamic Therapy Of Bladder Cancermentioning

confidence: 99%

See 2 more Smart Citations

Recent Progress in Nanomaterial-Based Biosensors and Theranostic Nanomedicine for Bladder Cancer

Song

Ding

et al. 2023

Biosensors

View full text Add to dashboard Cite

show abstract

“…In essence, systematically administered vaccines like BCG fail to generate adequate protective responses at mucosal surfaces [5]. Nowadays, complex nanoparticles (NPs) carrying antigens are of particular interests for vaccine development because of their adjuvant effects on the modulation of immune response [6][7][8][9][10]. NPs have been extensively explored to cope with the instability and toxicity frequently interrelated with the administration of soluble molecules [11].…”

Section: Introductionmentioning

confidence: 99%

A polymeric co-assembly of subunit vaccine with polyoxometalates induces enhanced immune responses

et al. 2021

Nano Res.

View full text Add to dashboard Cite

Long-lasting protective immune responses are expected following vaccination. However, most vaccines alone are inability to evoke an efficient protection. The combinatory administration of adjuvants with vaccines is critical for generating the enhanced immune responses. Herein, with biocompatible poly(4-vinylpyridine) (P4VP) as template, 2.5 nm iron/molybdenum oxide cluster, {Mo 72 Fe 30 }, is applied as an adjuvant to co-assemble with antigens of Mycobacterium bovis via hydrogen bonding at molecular scale. Molecular scale integration of the antigens and {Mo 72 Fe 30 } and their full exposure to body fluid media contribute to the augmentation of both humoral and cellular immune responses of the vaccines after inoculation in mice. Anti-inflammatory factor IL-10 gradually increases after 2 weeks followed by a final back to normal level by the 5th week. The balance between proinflammatory cytokines and anti-inflammatory factors suggests that immune system can be activated in the early stage of infection by the antigens carried by the supra-particles and secrete acute inflammatory factors for host defense and antiinflammatory factors for immune protection. Electronic Supplementary Material Supplementary material (further structural analysis and biological analsyis) is available in the online version of this article at 10.1007/s12274-021-4004-9.

show abstract

Designing Intelligent Nanomaterials to Achieve Highly Sensitive Diagnoses and Multimodality Therapy of Bladder Cancer

Chen

et al. 2023

Small Methods

View full text Add to dashboard Cite

Bladder cancer (BC) is among the most common malignant tumors of the genitourinary system worldwide. In recent years, the rate of BC incidence has increased, and the recurrence rate is high, resulting in poor quality of life for patients. Therefore, how to develop an effective method to achieve synchronous precise diagnoses and BC therapies is a difficult problem to solve clinically. Previous reports usually focus on the role of nanomaterials as drug delivery carriers, while a summary of the functional design and application of nanomaterials is lacking. Summarizing the application of functional nanomaterials in high‐sensitivity diagnosis and multimodality therapy of BC is urgently needed. This review summarizes the application of nanotechnology in BC diagnosis, including the application of nanotechnology in the sensoring of BC biomarkers and their role in monitoring BC. In addition, conventional and combination therapies strategy in potential BC therapy are analyzed. Moreover, different kinds of nanomaterials in BC multimodal therapy according to pathological features of BC are also outlined. The goal of this review is to present an overview of the application of nanomaterials in the theranostics of BC to provide guidance for the application of functional nanomaterials to precisely diagnose and treat BC.

show abstract

Smart nanocarriers as therapeutic platforms for bladder cancer

Cited by 9 publications

References 158 publications

Recent Progress in Nanomaterial-Based Biosensors and Theranostic Nanomedicine for Bladder Cancer

Recent Progress in Nanomaterial-Based Biosensors and Theranostic Nanomedicine for Bladder Cancer

A polymeric co-assembly of subunit vaccine with polyoxometalates induces enhanced immune responses

Designing Intelligent Nanomaterials to Achieve Highly Sensitive Diagnoses and Multimodality Therapy of Bladder Cancer

Contact Info

Product

Resources

About